With Thermo Fisher Acquiring Life Tech, RNAi Reagent Space Consolidates Further | GenomeWeb

Thermo Fisher Scientific this week announced that it will acquire Life Technologies for $13.6 billion in a deal that will bring together two of the largest providers of RNAi research products into a single entity.

The transaction also marks the latest in a series of mergers and acquisitions by both companies and their predecessors over the years that transformed the RNAi reagent field from a market served by small, niche players to one controlled by a few life science giants.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.